Bruno Michon

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

Steven E. Lipshultz, Rebecca E. Scully, Stuart R. Lipsitz et al. · The Lancet Oncology · 2010 · 442 citations · Full text

Drug Safety, Hematological Malignancy, Oncology +9

Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes

Steven E. Lipshultz, Tracie L. Miller, Rebecca E. Scully et al. · Journal of Clinical Oncology · 2012 · 319 citations · Full text

Postinduction Dexamethasone and Individualized Dosing of <i>Escherichia Coli</i> L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01

Lynda M. Vrooman, Kristen E. Stevenson, Jeffrey G. Supko et al. · Journal of Clinical Oncology · 2013 · 308 citations · Full text

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000)

Lewis B. Silverman, Kristen E. Stevenson, Jane E. O’Brien et al. · Leukemia · 2009 · 307 citations · Full text

Hematological Malignancy, Oncology, Pediatric Hematology +8

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial

Andrew E. Place, Kristen E. Stevenson, Lynda M. Vrooman et al. · The Lancet Oncology · 2015 · 234 citations

Medicine, Microbiology, Open-label Phase 3 +1